The useful answer is this: “start low and go slow” is a prescriber-led caution principle, not a public instruction to change your own medical cannabis plan.
Patients may hear the phrase during a consultation, follow-up, or discussion about side effects. It can be a helpful idea when it means careful prescribing, monitoring, and honest reporting. It becomes unsafe when it turns into guesswork about dose, route, product, timing, or how quickly to change treatment.
This guide is general UK patient information. It is not medical advice, dosing advice, route advice, product advice, or a treatment plan. If you have been prescribed medical cannabis and are unsure what to do, ask the prescribing team, pharmacist, or another qualified healthcare professional.
For wider context, start with the MCPH patient guide, then read the safety pages on medical cannabis side effects and THC side effects and impairment.
What the phrase is trying to protect against
“Start low and go slow” is usually trying to protect against avoidable problems: side effects, impairment, interactions, poor tolerability, and changes that happen too quickly for the patient and prescriber to understand.
That does not make the phrase proof of safety. It also does not mean every patient should follow the same pattern. Medical cannabis prescribing depends on the patient, diagnosis, previous treatments, other medicines, risk factors, product, route, and monitoring plan.
NHS medical cannabis guidance says possible side effects can include dizziness, tiredness, mood or behaviour change, feeling high, hallucinations, and suicidal thoughts, depending on the type of medical cannabis used. NHS guidance also says CBD and THC can affect how other medicines work.
So the caution is real. The action is still clinical review, not self-adjustment.
Why it is not dosing advice
A phrase is not a prescription.
The prescriber is responsible for deciding whether a cannabis-based medicinal product is appropriate, what is prescribed, how it is taken, how risks are monitored, and what happens if side effects appear. NICE guidance expects prescribers to discuss possible benefits and harms, dependence risk, mental health and medical history, interactions with other medicines, and ability to drive.
GMC guidance also keeps CBPM prescribing within specialist responsibility and professional competence, especially where unlicensed medicines are involved. NHS England guidance frames prescribing as a clinical decision that considers the patient, condition, other medicines, evidence, safety, and licensed alternatives.
That is why MCPH cannot turn “start low and go slow” into numbers, timings, route instructions, product suggestions, or a private adjustment plan. The safe public version is simple: understand the reason for caution, follow the plan you have been given, and ask for review if something is unclear or not working.
What to ask before starting or at review
A good consultation or review does not need perfect medical language. It needs honest information.
Useful questions include:
- What does “start low and go slow” mean in my actual treatment plan?
- Which side effects should I report quickly?
- Who do I contact if I feel impaired, unusually tired, dizzy, anxious, confused, or not myself?
- Could this interact with any of my prescribed medicines, pharmacy medicines, supplements, or cannabinoid products?
- What should I do if I miss or misunderstand an instruction?
- Are there any mental health, liver, kidney, cardiovascular, respiratory, pregnancy, breastfeeding, immune-system, or substance-use risks that change the review?
- What should I know about driving, work, caring, or safety-critical tasks?
Those questions do not ask the article to make clinical decisions. They help the clinical team give a clearer answer.
Side effects, impairment, and interactions matter
If “going slow” is part of a medical cannabis plan, monitoring is the other half of the idea. A slower plan is not useful if side effects are hidden, dismissed, or guessed around.
Tell the prescribing team about new or worsening symptoms, side effects, mood changes, impairment, sleepiness, dizziness, feeling high, hallucinations, suicidal thoughts, or anything that affects daily safety. If you are worried about other medicines, read MCPH’s guide to medical cannabis and medication interactions and take a full medicine list to the prescriber or pharmacist.
If symptoms feel serious, frightening, or unsafe, use the contact route you have been given by the clinic or an appropriate NHS urgent-care route. For broader guidance on worsening symptoms, read what to do if medical cannabis makes symptoms worse.
For driving, the boundary stays strict. A prescription is not blanket driving clearance, and a public article cannot decide whether you are fit to drive. If a medicine affects alertness, judgement, reaction time, mood, or coordination, that is a safety issue for the prescriber and official driving guidance.
If you think you have taken too much
This is where the phrase “start low and go slow” becomes very real. Some patients only understand why the advice exists after they have felt too impaired, too anxious, too sedated, too dizzy or simply not themselves.
If you think you have taken too much, do not panic and do not try to fix it by adding more cannabis or another cannabinoid product. Stop doing safety-critical things, do not drive, and use the contact route your clinic or pharmacy gave you. If you are with someone you trust, tell them what has happened so they can help you stay safe while you work out the next step.
The right response depends on what is happening. Feeling unpleasantly high, sleepy or anxious may need reassurance, observation and a clinic review. Severe confusion, chest pain, fainting, hallucinations, suicidal thoughts, severe distress, breathing problems or any immediate risk of harm needs urgent medical help.
Afterwards, write down what happened in plain language: what you took according to the prescription, when it happened, what you felt, how long it lasted, whether anything else was involved, and whether you felt impaired. That gives the clinic something useful to work with. The goal is not to blame yourself. It is to make the plan safer and clearer.
What not to do with the phrase
Do not use “start low and go slow” as permission to experiment. Do not change the prescribed plan, alter the route, combine products, add non-prescribed cannabis, use online cannabinoid products, or copy what worked for someone else.
Also avoid turning side effects into a private troubleshooting project. If a side effect appears, it may be tied to the product, route, other medicines, medical history, timing, sleep, food, alcohol, illness, mental health, or something unrelated. A public article cannot separate those safely.
The practical next step is boring but useful: keep clear notes, report what happened, and ask the prescriber what the phrase means for your plan.
FAQ
Is “start low and go slow” a dose instruction?
No. It is a caution phrase that only becomes meaningful inside an individual treatment plan from a prescriber.
Can I slow down or change my plan myself?
Do not change dose, route, product, timing or frequency without clinical advice. If the plan is unclear or difficult to follow, ask the prescribing team or pharmacist.
Does starting cautiously remove the risk of side effects?
No. Side effects, impairment and interactions can still happen. Report concerns promptly and follow the review route you were given.
What should I do if I feel too high or too impaired?
Do not drive or do anything safety-critical. Do not take more to try to balance it out. Contact your clinic, pharmacist, NHS 111 or urgent care depending on how serious the symptoms are. If there is immediate danger, use emergency help.
Should I hide it from the clinic if I took too much?
No. Tell the clinic honestly. They need to know what happened so they can review the plan, instructions, product, route, dose or monitoring.
What should I track between reviews?
Track what the prescriber asks you to track, such as symptoms, side effects, impairment, sleep, mood, function and missed or unclear instructions.
Sources
- NHS: Medical cannabis – https://www.nhs.uk/medicines/medical-cannabis/
- NICE NG144 recommendations: Cannabis-based medicinal products – https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NICE evidence review E: prescribing cannabis-based medicinal products – https://www.nice.org.uk/guidance/ng144/evidence/e-prescribing-cannabisbased-medicinal-products-pdf-6963831762
- GMC: Information for doctors on cannabis-based products for medicinal use – https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
- NHS England: Cannabis-based products for medicinal use – https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- MHRA/GOV.UK: Supply unlicensed medicinal products, also known as specials – https://www.gov.uk/government/publications/supply-unlicensed-medicinal-products-specials
- CQC: Cannabis-based medicinal products: what CQC expects from providers – https://www.cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-what-cqc-expects-providers
Cover image: TOPIC-025-cover-start-low-and-go-slow.png.
